Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.
Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...
Study finds substantial concordance between PSMA-PET and conventional imaging for primary prostate cancer staging. Using prostate-specific membrane antigen positron emission tomography (PSMA-PET) for ...
Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...
A panel of experts offers guidance for selecting patients with mCRPC for treatment with 177Lu-PSMA-617 and for managing treatment-related toxicities. The treatment is approved for use in men with ...
News-Medical.Net on MSN
New trial aims to improve both survival and quality of life for men with advanced prostate cancer
The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...
An overview of metastatic castration-resistant prostate cancer (mCRPC) and the role of PSMA in mCRPC. Alicia Morgans, MD: Welcome to the CURE Connections® program on radiopharmaceutical PSMA [prostate ...
Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...
The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer. The FDA has approved ...
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback